Kalaris Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is KLRS moving today?
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for KLRS.
KLRS insider activity
Kalaris Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net buying: $21.2M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | 2026-05-20 | AKKARAJU SRINIVAS | Insider | buy | $4.83 | 244,300 | 2,224,147 | $1.2M | SEC Form 4 |
| 2026-03-23 | 2026-03-20 | Hagen Brett R | Insider | sell | $6.72 | 1,915 | Not reported | $13K | SEC Form 4 |
| 2026-02-17 | 2025-12-18 | AKKARAJU SRINIVAS | Insider | buy | $10.42 | 479,847 | 1,979,847 | $5.0M | SEC Form 4 |
| 2025-12-22 | 2025-12-22 | AKKARAJU SRINIVAS | Insider | buy | $10.00 | 1,500,000 | 1,500,000 | $15.0M | SEC Form 4 |
KLRS contract awards, year to date.
Public federal awards linked to this ticker.
KLRS lobbying filings, year to date.
Registered lobbying filings matched to Kalaris Therapeutics, Inc. Common Stock.